profit from every £100 of sales.
£0£100
Genus
£22.80-0.61% today
-7.3% in 1 year
1-year low £19.661-year high £31.70
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Genus sold, what it kept, and what it did with the cash.
Sales went from £593 million in 2022 to £673 million in 2025.
SalesProfit
Genus handed back 43% of the cash it generated last year.
£21M
Free cash flow 2025£49M
Bought back its own shares–
Paid as dividends£21M
Cash vs. debt£48M vs. £266M
Genus vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from £100 of sales | Sales growth a year | Price per £1 of profit |
|---|---|---|---|
| Genus | No profit yet | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Genus's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of GBP | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 593 | 690 | 669 | 673 | |
| 148 | 188 | 179 | – | |
| 51 | 44 | 6 | 42 | |
| 93 | 97 | 74 | 94 | |
| – | – | – | – | |
| 0.62 | 0.51 | 0.12 | 0.25 | |
| 24.9% | 27.2% | 26.7% | – | |
| 8.7% | 6.4% | 1.0% | 6.3% | |
| – | – | – | – |
Balance sheet
| In millions of GBP | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 1,018 | 966 | 988 | 899 |
| Cash | 39 | 36 | 43 | 48 |
| Total debt | 224 | 232 | 291 | 266 |
| Total liabilities | 446 | 430 | 474 | 423 |
| 573 | 545 | 518 | 476 | |
| 66 | 66 | 66 | 67 | |
| 5.1% | 5.2% | 2.5% | 5.0% | |
| – | – | – | – |
Cash flow
| In millions of GBP | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 34 | 50 | 30 | 67 | |
| 65 | 35 | 25 | 19 | |
| -31 | 15 | 5 | 49 | |
| Dividends paid | 21 | 21 | 21 | 21 |
| – | – | – | – | |
| 4 | 6 | 7 | 7 |
Valuation
- –
- –
- –
- 3.0×
- 2.2×
- 30.2×
- 18.0×
- 3.3%
- –
- 1.4%
Profitability
- –
- 6.3%
- –
- –
- 5.0%
- 4.4%
- –
- –
- –
- –
Growth
- +4.3%
- −26.6%
- –
- –
- +0.6%
Financial health
- 2.3×
- 0.56
- –
- 2.4×
- 1.94
- –
- –
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 47%of 952
Bottom 40%of 883
Bottom 28%of 888
Top 33%of 987
1.4%of the share price, paid each year
On $1,000 invested$14a year at today's yield, before tax
–per share
Raised–not every year
How safe it looks
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
23No pass
Benjamin Graham
30No pass
Philip Fisher
22No pass
Peter Lynch
19No pass
Joel Greenblatt
0No pass
Charlie Munger
21No pass
Terry Smith
21No pass
Questions about Genus
Is Genus a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Genus AI analysis
What does Genus do?
Genus plc produces and sells animal genetics to farmers in North America, Latin America, the United Kingdom, the rest of Europe, the Middle East, Russia, Africa, and Asia. The company operates through three segments: Genus PIC, Genus ABS, and Genus Research and Development. It is in Biotechnology, based in Basingstoke, United Kingdom, with 3,190 employees.
Does Genus pay a dividend?
Yes. At today's price the dividend is 1.4% a year. In 2025 it paid out £21.1 million in dividends.
Is Genus stock halal?
Yes. Genus passes our halal screen: its business is permitted and its debt is 18% of its market value, under the 30% limit. How we check
How has Genus stock done over the past year?
Down 7.3% over the past twelve months, to £22.80. It traded between £19.66 and £31.70 and is 28.1% below its high.
Who are Genus's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Genus's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.